Ludwig Maximilian University Hospital
Munich, Bavaria, 81377, Germany
NCT Number: NCT05193825
Deep brain stimulation (DBS) represents the treatment of choice for advanced stages of Parkinson's disease (PD). Currently, adaptive closed-loop stimulation systems that apply disease-specific biomarkers, such as local field potentials (LFPs), are being actively examined to facilitate DBS programming. However, the most suitable feedback signal, still remains to be determined. The investigators previously tested the usefulness of the patient's subjective rating on a visual analogue scale (VAS) as a potential feedback signal for DBS adjustment and found that VAS-based programming lead to similar results as our standard approach. One of the practical advantages of using VAS-based programming strategies - in addition to saving time - is the principal applicability of such an approach to a remote programming setting, although a validation of such an approach is required. Within the scope of a prospective, randomized multicenter clinical trial (the REMOTE Trial), the investigators will examine the effectiveness and safety of VAS-based remote DBS programming in PD by using a novel and recently introduced software platform (Abbott NeurosphereTM Virtual Clinic) that allows for the programming through a smartphone-based video connection with the patient. Therefore, n = 50 PD patients undergoing STN-DBS surgery will be randomized and subsequent to surgery will have their IPG settings adjusted either during regular visits at the hospital or alternatively be programmed remotely through a VAS-based approach. Prior to surgery and after a 90 days follow-up period, we will assess specific clinical (MDS-Unified Parkinson's Disease Rating Scale = UPDRS, Parkinson's Disease Questionnaire-39 sum index = PDQ-39 SI, Beck Depression Inventory = BDI, Montreal Cognitive Assessment Scale = MOCA) parameters to determine the effectivity and safety of the two different strategies on the patient outcome and to correlate it with VAS ratings and MRI data. The results will support the examination of remote-based DBS programming and evaluate the patient's subjective judgment as a valid feedback signal.
Looking for future studies?
Notify Me35 year–80 year
All sexes
Interventional
Not applicable
Munich, Bavaria, 81377, Germany
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients in the experimental group (Group B) will have their internal pulse generators (IPGs) adjusted through a novel software that allows for remote DBS programming (NeurosphereTM Virtual Clinic)
Patients in the active comparator group (Group A) will have their internal pulse generators (IPGs) adjusted through a standard procedure at their caregivers institution.
Time frame: Assessed at Day 90
Part III of the MDS-Unified Parkinson's Disease Rating Scale (Range 0-128 pts. with high values indicating a more severe disease symptoms)
Time frame: Assessed at day -1 and +90 (day 0 = implantation of DBS electrodes)
Part I of the MDS-Parkinson's Disease Rating Scale (Range 0-52 pts. with high values indicating more severe disease symptoms)
Time frame: Assessed at day -1 and +90 (day 0 = implantation of DBS electrodes)
Part II of the MDS-Parkinson's Disease Rating Scale (Range 0-52 pts. with high values indicating more severe disease symptoms)
Time frame: Assessed at day -1 and +90 (day 0 = implantation of DBS electrodes)
Part IV of the MDS-Parkinson's Disease Rating Scale (Range 0-24 pts. with high values indicating more severe disease symptoms)
Time frame: Assessed at day -1 and +90 (day 0 = implantation of DBS electrodes)
Parkinson's Disease Questionnaire-39 Sum Index (Range 0-100 pts. with high values indicating more severe disease symptoms)
Time frame: Assessed on a weekly basis by the patient between day +5 and +90 (day 0 = implantation of DBS electrodes)
Number of hours spent with bothersome dyskinesia or in a reduced mobility state (OFF)
Time frame: Assessed at day +90 (day 0 = implantation of DBS electrodes)
Number of doctor-patient contacts either in person at the hospital (Group A) or remotely (Group B)
Time frame: Assessed at day +5 and +90 (day 0 = implantation of DBS electrodes)
Total Electrical Energy Delivered by the IPG; TEED (1s) = (voltage2 × frequency × pulsewidth) / impedance (1s)
Thomas Köglsperger
Other
Evaluation of a Visual-Analog Scale (VAS) for Remote DBS Programming
Acronym: REMOTE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05905302
Basal Ganglia Diseases, Brain Diseases
Cleveland, Ohio, United States
View Trial DetailsNCT04922411
Basal Ganglia Diseases, Brain Diseases
St Louis, Missouri, United States
View Trial DetailsNCT05103384
Basal Ganglia Diseases, Brain Diseases
Cleveland, Ohio, United States
View Trial DetailsNCT05833308
Basal Ganglia Diseases, Brain Diseases
Shanghai, Shanghai Municipality, China
View Trial Details